Stockscreener 앱 받기
5.36
2.29%
0.12
시간 외 거래:
5.32
-0.04
-0.75%
전일 마감가:
$5.24
열려 있는:
$5.155
하루 거래량:
663.73K
Relative Volume:
0.85
시가총액:
$374.79M
수익:
$380.79M
순이익/손실:
$49.27M
주가수익비율:
7.6571
EPS:
0.7
순현금흐름:
$10.68M
1주 성능:
+34.67%
1개월 성능:
+41.80%
6개월 성능:
+0.94%
1년 성능:
+201.12%
1일 변동 폭
$5.1505
$5.465
1주일 범위
$3.94
$5.465
52주 변동 폭
$1.575
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-683-0917
주소
43 THORNDIKE STREET, CAMBRIDGE
AMLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
5.36 | 374.79M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Stock Surge: Amylyx Pharmaceuticals Inc (AMLX) Closes at 3.00, Marking a -9.09 Increase/Decrease - DWinneX
What is the investor’s view on Amylyx Pharmaceuticals Inc (AMLX)? - uspostnews.com
Recent Insider Activity Could Benefit Amylyx Pharmaceuticals Inc (AMLX) - knoxdaily.com
Amylyx Pharmaceuticals Inc Shares Are Up 148.48% Since The Beginning Of The Year - Marketing Sentinel
Amylyx Pharmaceuticals Inc (AMLX) Stock: A Year of Market Fluctuations - investchronicle.com
Press Release Distribution & PR Platform - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
Q1 Earnings Forecast for AMLX Issued By Leerink Partnrs - Defense World
Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - markets.businessinsider.com
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by American Century Companies Inc. - Defense World
American Century Companies Inc. Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - The AM Reporter
Wellington Management Group LLP Acquires Shares of 209,708 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - The AM Reporter
Wellington Management Group LLP Makes New $793,000 Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Amylyx upgraded at Mizuho on potential of lead asset - MSN
First subject dosed in Amylyx’s Phase I trial of ALS therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis - BioSpace
Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral Sclerosis - marketscreener.com
Breakthrough ALS Treatment Enters Human Trials: Amylyx Targets New Disease Mechanism - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Is Now The Time To Buy Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Stock? - stocksregister.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Rating Increased to Outperform at Mizuho - Defense World
Mizuho Upgrades Amylyx Pharmaceuticals (AMLX) - Nasdaq
Amylyx stock upgraded at Mizuho on lead asset (AMLX:NASDAQ) - Seeking Alpha
Mizuho lifts Amylyx stock rating, doubles price target to $7 - Investing.com
Mizuho lifts Amylyx stock rating, doubles price target to $7 By Investing.com - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - markets.businessinsider.com
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Don't Ignore The Insider Selling In Amylyx Pharmaceuticals - simplywall.st
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Amylyx Pharmaceuticals co-CEO Justin Klee sells $74,454 in stock - Investing.com Australia
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking - simplywall.st
Amylyx Pharmaceuticals Executives Unload Massive Stock Shares! - TipRanks
Amylyx Pharmaceuticals co-CEO Justin Klee sells $74,454 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals chief medical officer sells $43,082 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals chief medical officer sells $43,082 in stock - Investing.com
Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals’ co-CEO Joshua Cohen sells $74,482 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView
Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock - Investing.com
Amylyx Pharmaceuticals’ co-CEO Joshua Cohen sells $74,482 in stock - Investing.com
Amylyx Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Amylyx Pharmaceuticals Set to Reveal Latest Corporate Strategy at Major Healthcare Conference - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Does Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Still Look Hot This Week? - stocksregister.com
Charles Schwab Investment Management Inc. Lowers Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):